STARS Trial Tests Whether a Synbiotic Can Preserve Bone Health in Older Women
An 18-month trial will test SBD111 for bone health in older women. Early findings address recruitment, not whether the treatment works.
Summary
Can supporting gut bacteria help older women maintain stronger bones? The STARS trial is testing SBD111, a fruit and vegetable-derived synbiotic medical food, against placebo in women aged 60 or older. The study plans to enroll 220 women for 18 months, measuring changes in spine bone density, bone strength, gut microbial function, and inflammation. This paper reports the study design and early recruitment findings—not treatment benefits. By July 2025, 42 women had enrolled. Digital outreach recruited women more than three times as quickly as traditional methods and required substantially less staff time, but cost more per participant: $548 versus $173. These findings could help researchers recruit older women more efficiently. Whether SBD111 protects bones or is safe remains unanswered in this abstract-only report.
Detailed Summary
Bone loss in older women raises fracture risk and can threaten mobility and independence. Researchers are testing whether changing gut microbes with a daily synbiotic, a combination intended to support beneficial bacteria, could help preserve bone density. This paper describes the STARS trial and its early recruitment experience, not treatment results.
The single-site trial plans to enroll 220 women aged 60 or older and follow them for 18 months. Participants are randomly assigned to SBD111, a fruit and vegetable-derived synbiotic medical food, or placebo, with participants and investigators unaware of assignments. The main outcome is change in lower-spine bone density; additional measures examine bone strength, gut microbial function, and inflammation.
Recruitment began in August 2024. By July 2025, 42 women had enrolled: 32 through digital outreach and 10 through traditional methods. Digital recruitment averaged 2.9 enrollments monthly versus 0.9 for traditional approaches. Reported staff requirements were substantially lower digitally, but costs per enrolled participant were higher: $548 compared with $173. Baseline characteristics and enrollment rates were similar across strategies.
These findings suggest digital outreach can accelerate recruitment of older women into nutrition and microbiome trials while reducing staff workload. However, its higher enrollment costs create a budget tradeoff. For patients and clinicians, the important question remains unanswered: whether SBD111 meaningfully preserves bone density or improves skeletal health. The reported findings do not support recommending it for osteoporosis prevention.
This summary is based on the abstract only. Recruitment findings come from one site and a small early sample, and the recruitment strategies were not described as randomly assigned. No efficacy, safety, or fracture results are reported. Several authors are affiliated with the product company, making full disclosure review important. Bone density is also a surrogate outcome, so any eventual improvement would not automatically establish fewer fractures. Treatment outcomes are still needed.
Key Findings
- STARS plans to test daily SBD111 against placebo for 18 months in 220 women aged 60 or older.
- Digital outreach enrolled 32 women versus 10 through traditional methods, averaging 2.9 versus 0.9 enrollments monthly.
- Digital recruitment required nearly tenfold less reported staff effort but cost $548 per enrollment versus $173 for traditional outreach.
- No treatment efficacy or safety results are reported; this paper does not establish that SBD111 prevents bone loss.
Methodology
STARS is an investigator-initiated, single-site, randomized, double-blind, placebo-controlled trial with an enrollment target of 220 women aged 60 or older. Its primary endpoint is proportionate change in lumbar spine bone mineral density over 18 months; secondary measures include CT-derived bone density and vertebral strength, gut microbial function, and biomarkers. This publication describes trial design and recruitment through July 2025 rather than intervention outcomes.
Study Limitations
This summary is based on the abstract only, without access to the full methods, eligibility criteria, or conflict-of-interest disclosures. Recruitment findings involve only 42 women at one site, and the abstract does not describe random assignment to recruitment strategies. No efficacy or safety outcomes are reported, and several authors have affiliations with the product company.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: